Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Pembrolizumab

5

X.k Sarcoid-like granulomatosis (endo-/extrathoracic)

1
Last update : 21/04/2016
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Atezolizumab
2
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
5
Ipilimumab
4
Lambrolizumab
4
Nivolumab
5
PD-1/PD-L1-inhibitors or blocking agents/drugs
5

Publications

Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature.
Journal of immunotherapy and precision oncology 2023 May;6;111-116 2023 May
Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission.
La Revue de medecine interne 2018 Feb;39;130-133 2018 Feb
Pembrolizumab reactivates pulmonary granulomatosis.
Respiratory medicine case reports 2017;22;126-129 2017
Pulmonary Sarcoidosis Activation following Neoadjuvant Pembrolizumab plus Chemotherapy Combination Therapy in a Patient with Non-Small Cell Lung Cancer: A Case Report.
Case reports in oncology 2017;10;1070-1075 2017
Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab.
Annals of oncology : official journal of the European Society for Medical Oncology 2016 Jun;27;1178-1179 2016 Jun
Pembrolizumab-associated sarcoidosis.
JAAD case reports 2016 Jul;2;290-3 2016 Jul

Powered by

  • ^
  • Contact
  • Cookies
  • About